TY  - JOUR
A1  - Obermüller, Nicholas
A1  - Rosenkranz, Alexander
A1  - Müller, Hans-Walter
A1  - Hidde, Dennis
A1  - Veres, András
A1  - Decker-Burgard, Sabine
A1  - Weisz, Isolde
A1  - Geiger, Helmut
T1  - Long-term therapy outcomes when treating chronic kidney disease patients with paricalcitol in German and Austrian clinical practice (TOP study)
T2  - International journal of molecular sciences
N2  - Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short-term data in clinical routine settings. A 12-month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008 to 2013. Laboratory values, demographical, and clinical data were documented in 629 dialysis patients and 119 predialysis patients. In predialysis patients, median intact parathormone (iPTH) was 180.0 pg/mL (n = 105) at the start of the study, 115.7 pg/mL (n = 105) at last documentation, and 151.8 pg/mL (n = 50) at month 12, with 32.4% of the last documented iPTH values in the KDOQI (Kidney Disease Outcomes Quality Initiative) target range. In dialysis patients, median iPTH was 425.5 pg/mL (n = 569) at study start, 262.3 pg/mL (n = 569) at last documentation, and 266.1 pg/mL (n = 318) at month 12, with 36.5% of dialysis patients in the KDOQI target range. Intravenous paricalcitol showed more homogenous iPTH control than oral treatment. Combined analysis of all dialysis patients indicated comparable and stable mean serum calcium and phosphate levels throughout the study. Clinical symptoms, such as itching, bone pain, and fatigue, were improved compared with study entry. The spectrum and frequency of adverse events mirrored the known pattern for patients on dialysis. Paricalcitol is efficacious and has a consistent safety profile in sHPT over 12 months.
KW  - parathormone (PTH)
KW  - paricalcitol
KW  - secondary hyperparathyroidism (sHPT)
KW  - chronic kidney disease (CKD)
KW  - dialysis
KW  - predialysis
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/46502
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-465029
SN  - 1422-0067
SN  - 1661-6596
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
VL  - 18
IS  - 10, Art. 2057
SP  - 1
EP  - 20
PB  - Molecular Diversity Preservation International
CY  - Basel
ER  -